Meeting
2019 ASCO Annual Meeting
Personalized response-driven adjuvant therapy after combination ipilimumab and nivolumab in high-risk resectable stage III melanoma: PRADO trial.
Authors
Irene Reijers
Netherlands Cancer Institute, Amsterdam, Netherlands
Irene Reijers , Elisa A. Rozeman , Alexander M. Menzies , Bart A. Van De Wiel , Hanna Eriksson , Karijn Suijkerbuijk , Astrid Aplonia Maria Van Der Veldt , Ellen Kapiteijn , Geke Hospers , Willem M.C. Klop , Andrew Spillane , Richard A. Scolyer , Inge Marie Svane , Lars Bastholt , Henrik Schmidt , James M.G. Larkin , Alexander Christopher Jonathan Van Akkooi , Georgina V. Long , Christian U. Blank
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Other Melanoma/Skin Cancers
Clinical Trial Registration Number
NCT02977052
Citation
J Clin Oncol 37, 2019 (suppl; abstr TPS9605)
DOI
10.1200/JCO.2019.37.15_suppl.TPS9605
Abstract #
TPS9605
Poster Bd #
170b
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Survival update of neoadjuvant ipilimumab + nivolumab in macroscopic stage III melanoma: The OpACIN and OpACIN-neo trials.
First Author: Judith M. Versluis
Poster
2020 ASCO Virtual Scientific Program
Personalized combination of neoadjuvant domatinostat, nivolumab and ipilimumab in macroscopic stage III melanoma patients stratified according to the interferon-gamma signature: The DONIMI study.
First Author: Irene L.M. Reijers
Poster
2022 ASCO Annual Meeting
The interferon-gamma (IFN-y) signature from baseline tumor material predicts pathologic response after neoadjuvant ipilimumab (IPI) + nivolumab (NIVO) in stage III melanoma.
First Author: Irene L.M. Reijers
Poster
2022 ASCO Annual Meeting
The NADINA trial: A multicenter, randomised, phase 3 trial comparing the efficacy of neoadjuvant ipilimumab plus nivolumab with standard adjuvant nivolumab in macroscopic resectable stage III melanoma.
First Author: Minke W. Lucas